News About: Goverment
New drug price determination process needs fundamental reform.
In a meeting on the subject of "Problems and reform programs for the drug pricing system of Korea" on May 11 sponsored by several civic groups, Mr. Woo Seok-gyun of the Korean Federation of Medical Groups for Health R...
KFDA to set review standards for clinical studies on 6 therapeutic groups.
The KFDA announced recently that the review standards for clinical studies would be gradually released initially for 6 therapeutic groups including the obesity, stomach cancer and depression therapy to cope with ever ...
New dosage technology clears sibutramine patent huddles.
A new dosage technology for sibutramine, the main active substance of a top anti-obesity drug, Reductil, has been developed, attracting keen interests to the pharmaceutical industry.
The technology developer, CTC B...
Pharmaceutical industry may collapse under KORUS FTA.
The Korea and U. S. FTA system may accelerate the domestic drug industry substantially to transform stemming from which the original branded drugs supplied by most of foreign multinational drug corporations may predom...
KFDA to investigate bio equivalency tests for 3,907 drugs.
The KFDA instructed all regional KFDA offices to investigate and report the bio equivalency tests for 3,907 drugs as to which companies assigned the tests or the company actually manufactured the drugs.
The investi...
Civic group calling for patented drug prices to reduce.
Two civic groups, People's Participatory Coalition and Health and Medical Coalition, announced a joint statement over the MOHW's optimizing plan for the NHI drug prices dated on May 5 that the drug price reduction pol...
Health Minister said "incompetent drug company to weed out"
As to the government's positive list system Minister Rhyu Shi-min urged the pharmaceutical industry to be cooperative amid the industry's harsh resistance against the system.
Minister Rhyu said on May 3 "The positi...
7.9% slash of prices after review on 4,517 drugs.
The MOHW has reviewed the total 4,517 drug prices 4 times since 2002 and made reductions by 7.9% on average. According to the status of the upper limited price reduction through the periodical price reviews, the total...
Defective system made indiscreet over production of copy drugs.
It is pointed out that the recent indiscreet production of too many copy drugs should be blamed for several defective administrative systems including 1) the current drug pricing system to allow 80% of the upper limit...
Wyeth Korea to extend Enbrel's NHI coverage term.
Wyeth Korea said that the NHI reimbursement period of Enbrel inj. would be remarkably extended for the treatment of ankylosing spondylitis taking effect from May this year according to the revised NHI payment standard...
